Biodesix Inc (NASDAQ: BDSX)’s stock price has gone rise by 7.48 in comparison to its previous close of 0.71, however, the company has experienced a -4.28% decrease in its stock price over the last five trading days. seekingalpha.com reported 2025-03-03 that Biodesix, Inc. (NASDAQ:BDSX ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Chris Brinzey – Investor Relations Scott Hutton – Chief Executive Officer Robin Harper Cowie – Chief Financial Officer Conference Call Participants Andrew Brackmann – William Blair Kyle Mikson – Canaccord Dan Brennan – TD Cowen Thomas Flaten – Lake Street Capital Markets William Bonello – Craig-Hallum Sung Ji Nam – Scotiabank Operator Good day and thank you for standing by. Welcome to the Biodesix’s Q4 2024 Earnings Conference Call.
Is It Worth Investing in Biodesix Inc (NASDAQ: BDSX) Right Now?
Moreover, the 36-month beta value for BDSX is 1.11. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BDSX is 73.74M and currently, short sellers hold a 1.06% of that float. On March 04, 2025, BDSX’s average trading volume was 345.60K shares.
BDSX’s Market Performance
BDSX stock saw a decrease of -4.28% in the past week, with a monthly decline of -25.60% and a quarterly a decrease of -46.22%. The volatility ratio for the week is 12.65%, and the volatility levels for the last 30 days are 8.66% for Biodesix Inc (BDSX). The simple moving average for the last 20 days is -15.57% for BDSX’s stock, with a simple moving average of -47.76% for the last 200 days.
Analysts’ Opinion of BDSX
Craig Hallum, on the other hand, stated in their research note that they expect to see BDSX reach a price target of $3. The rating they have provided for BDSX stocks is “Buy” according to the report published on July 26th, 2024.
TD Cowen gave a rating of “Buy” to BDSX, setting the target price at $2.80 in the report published on May 13th of the previous year.
BDSX Trading at -31.48% from the 50-Day Moving Average
After a stumble in the market that brought BDSX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.44% of loss for the given period.
Volatility was left at 8.66%, however, over the last 30 days, the volatility rate increased by 12.65%, as shares sank -24.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.32% lower at present.
During the last 5 trading sessions, BDSX fell by -5.06%, which changed the moving average for the period of 200-days by -49.16% in comparison to the 20-day moving average, which settled at $0.9073. In addition, Biodesix Inc saw -49.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BDSX starting from Vazquez Chris, who sale 3,630 shares at the price of $0.92 back on Feb 11 ’25. After this action, Vazquez Chris now owns 17,623 shares of Biodesix Inc, valued at $3,355 using the latest closing price.
Pestano Gary Anthony, the Chief Development Officer of Biodesix Inc, sale 16,748 shares at $0.92 during a trade that took place back on Feb 11 ’25, which means that Pestano Gary Anthony is holding 156,008 shares at $15,479 based on the most recent closing price.
Stock Fundamentals for BDSX
Current profitability levels for the company are sitting at:
- -0.53 for the present operating margin
- 0.78 for the gross margin
The net margin for Biodesix Inc stands at -0.67. The total capital return value is set at -0.38. Equity return is now at value -331.82, with -46.24 for asset returns.
Based on Biodesix Inc (BDSX), the company’s capital structure generated 0.69 points at debt to capital in total, while cash flow to debt ratio is standing at -0.9. The debt to equity ratio resting at 2.22. The interest coverage ratio of the stock is -3.91.
Currently, EBITDA for the company is -34.5 million with net debt to EBITDA at -1.03. When we switch over and look at the enterprise to sales, we see a ratio of 2.25. The receivables turnover for the company is 8.16for trailing twelve months and the total asset turnover is 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.40.
Conclusion
To wrap up, the performance of Biodesix Inc (BDSX) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
